Pardes Biosciences, Inc. (PRDS)

Market Cap	118.22M
Revenue (ttm)	n/a
Net Income (ttm)	-107.38M
Shares Out	61.73M
EPS (ttm)	-11.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,692
Open	2.00
Previous Close	2.01
Day's Range	1.87 - 2.00
52-Week Range	0.75 - 13.01
Beta	n/a
Analysts	Buy
Price Target	10.54 (+450.39%)
Earnings Date	n/a

About PRDS

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 63
• Stock Exchange: NASDAQ
• Ticker Symbol: PRDS

Analyst Forecast

According to 9 analysts, the average rating for PRDS stock is "Buy." The 12-month stock price forecast is $10.54, which is an increase of 450.39% from the latest price.

Price Target

$10.54

(450.39% upside)

Analyst Consensus: Buy